ReviewJID innovations : skin science from molecules to population health2026
The tumor microenvironment of cutaneous squamous cell carcinoma in high-risk patient groups: A scoping review.
Review in JID innovations : skin science from molecules to population health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The skin-specific long non-coding RNA TEDAR orchestrates late epidermal differentiation via an ERK-KLF4 cytoplasmic regulatory axis.Cell death & disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cutaneous squamous cell carcinoma (cSCC) is a prevalent skin cancer in the general population that poses so far unresolved challenges in high-risk groups such as organ transplant recipients and individuals with recessive dystrophic epidermolysis bullosa. Although most cases of cSCC respond well to standard treatments, these 2 groups often face more aggressive disease, characterized by higher rates of metastasis and cancer-specific mortality. The tumor microenvironment plays a pivotal role in cSCC progression, influencing tumor growth, immune evasion, and therapy response. Therefore, this scoping review aims to systematically investigate how the tumor microenvironment in these high-risk cSCC differs from that of sporadic cSCC, highlight shared tumorigenic mechanisms, and identify knowledge gaps for future research. Specifically, we review immune cell infiltration, epithelial-mesenchymal transition, extracellular matrix remodeling, and related biomarkers, while also exploring potential therapeutic targets. It is surmised that both organ transplant recipients cSCC and recessive dystrophic epidermolysis bullosa cSCC may exhibit a permissive tumor microenvironment, potentially characterized by immune dysfunction and enhanced TGFβ signaling, contributing to tumor aggressiveness. Notably, organ transplant recipients cSCC primarily demonstrates immune exhaustion, whereas recessive dystrophic epidermolysis bullosa cSCC is driven by chronic tissue damage with concomitant extracellular matrix remodeling. A better understanding of tumor microenvironment features in these high-risk cSCC may help develop novel targeted therapies to improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.